Trevi Therapeutics, Inc. (TRVI) — Analyst outlook / Analyst consensus target is. Based on 17 analyst ratings, the consensus is bullish — 1 Strong Buy, 16 Buy.
The consensus price target is $19.25 (low: $16.00, high: $24.00), representing an upside of 37.1% from the current price $14.04.
Analysts estimate Earnings Per Share (EPS) of $-0.51 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.47 vs est $-0.51 (beat +7.3%). 2025: actual $-0.29 vs est $-0.36 (beat +20.4%). Analyst accuracy: 83%.
TRVI Stock — 12-Month Price Forecast
$19.25
▲ +37.11% Upside
Average Price Target
Based on 17 Wall Street analysts offering 12-month price targets for Trevi Therapeutics, Inc., the average price target is $19.25, with a high forecast of $24.00, and a low forecast of $16.00.
The average price target represents a +37.11% change from the last price of $14.04.
Highest Price Target
$24.00
Average Price Target
$19.25
Lowest Price Target
$16.00
TRVI Analyst Ratings
Buy
Based on 17 analysts giving stock ratings to Trevi Therapeutics, Inc. in the past 3 months
EPS Estimates — TRVI
83%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.47
vs Est –$0.51
▲ 7.9% off
2025
Actual –$0.29
vs Est –$0.36
▲ 25.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — TRVI
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
